Risperidone oral soluble Pellicles(Qilu Pharma)

利培酮口溶膜（齐鲁制药）

Report date: 2025/07/29 13:23:44

Base Information

Drug NameRisperidone oral soluble Pellicles(Qilu Pharma)
Drug Alias NameRisperidona利司哌酮Risperidonum利螺环酮Risperdal Consta (利培酮) +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsSchizophreniaAutistic DisorderBipolar Disorder
Global Approved IndicationsSchizophreniaAutistic DisorderBipolar Disorder
Approved Indications in ChinaSchizophreniaAutistic DisorderBipolar Disorder
Original Approved Country/TerritoryMainland China
Original Approved Date2025/07/22
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesQilu Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSchizophreniaAutistic DisorderBipolar Disorder
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG